Pudongia also continues its excellent launch trajectory with strong demand in both endemic and travel markets.

May 8, 2025 / CEO / receipt, needs a key / Christophe Weber, CEO | earnings call 2025-05-08 | transcript c4f58a88-c394-45af-b2ef-c75c08e4a14c | chars 4463-4573 | segment 4

CUDENGA is available in 17 European countries, and travel recommendations support its use to help protect travelers to dengue-endemic areas.

Feb 1, 2024 / CEO / receipt, needs a key / Christophe Weber, CEO | earnings call 2024-02-01 | transcript c0f66767-d057-40d7-9210-239de57e810f | chars 8032-8172 | segment 8

Our dengue vaccine, Scudenga, was recently approved in Argentina and Thailand, and we are pleased with the momentum we are seeing in both endemic and travel market.

Jul 27, 2023 / CEO / receipt, needs a key / Christophe Weber, CEO | earnings call 2023-07-27 | transcript 5f17419c-ea0f-4fdc-8063-fc5027f57dfd | chars 3256-3420 | segment 3